Firebrick Pharma
Parkville, Australia· Est.
Australian biotech delivering PVP‑I nasal sprays for rapid viral inactivation and common cold treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech delivering PVP‑I nasal sprays for rapid viral inactivation and common cold treatment.
Respiratory Infections
Technology Platform
Low‑dose (0.5%) povidone‑iodine (PVP‑I) formulation delivered via a custom nasal spray pump, providing rapid, broad‑spectrum viral inactivation with minimal resistance risk.
Opportunities
Geographic expansion into Europe, Asia and and North America, plus potential licensing of the PVP‑I platform for prophylactic or therapeutic uses against emerging respiratory viruses.
Risk Factors
Regulatory approval hurdles in major markets, competition from other antiviral nasal sprays, and consumer acceptance of an iodine‑based over‑the‑counter product.
Competitive Landscape
Few competitors offer broad‑spectrum antiviral nasal sprays; Firebrick differentiates through PVP‑I’s rapid viral kill and low resistance potential, but must compete with established symptomatic cold remedies and emerging antiviral agents.